Sanofi leapfrogs Amgen with US priority review for alirocumab
This article was originally published in Scrip
Sanofi and its partner Regeneron Pharmaceuticals have edged in ahead in the race to bring the first PCSK9 inhibitor to market in the US. The US FDA has granted their drug Praluent (alirocumab) a priority review, giving it a target action date of 24 July 2015. Amgen, with its rival product evolocumab, has a target date of 27 August.